Meningioma, Familial, Susceptibility To

Description

Meningiomas are, in general, slowly growing benign tumors derived from the arachnoidal cap cells of the leptomeninges, the soft coverings of the brain and spinal cord. Meningiomas are believed to be the most common primary tumors of the central nervous system in man. The vast majority of meningiomas are sporadic; familial occurrence of meningioma is rare (Zang, 2001).Familial or multiple meningiomas may also be seen in tumor predisposition syndromes. Some patients with schwannomatosis (OMIM ), caused by mutation in the SMARCB1 gene, may develop meningiomas. One patient with malignant gliomas (GLM2 ) associated with a mutation in the PTEN gene (OMIM ) developed a meningioma (Staal et al., 2002).

Clinical Features

Phenotypes and symptoms related to Meningioma, Familial, Susceptibility To

  • Neoplasm
  • Meningioma
  • Medulloblastoma
  • Neoplasm of the central nervous system

Incidence and onset information

Not enough data available about incidence and published cases.
No data available about the known clinical features onset.

Researches and researchers

Currently, we don't have any information about doctors, researches or researchers related to this disease. Please contact us if you would like to appear here.


Mendelian

Accelerate your rare disease diagnosis with us

Learn more

Meningioma, Familial, Susceptibility To Recommended genes panels

Panel Name, Specifity and genes Tested/covered
PTEN Comprehensive - Sequence & Deletion/Duplication Analysis.

By Baylor Miraca Genetics Laboratories (United States).

PTEN
Specificity
100 %
Genes
17 %
PTEN Deletion/Duplication Analysis.

By Baylor Miraca Genetics Laboratories (United States).

PTEN
Specificity
100 %
Genes
17 %
PTEN Deletion/Duplication Analysis (Prenatal Diagnosis).

By Baylor Miraca Genetics Laboratories (United States).

PTEN
Specificity
100 %
Genes
17 %
PTEN Sequence Analysis.

By Baylor Miraca Genetics Laboratories (United States).

PTEN
Specificity
100 %
Genes
17 %
PTEN Sequence Analysis (Familial Mutation/Variant Analysis).

By Baylor Miraca Genetics Laboratories (United States).

PTEN
Specificity
100 %
Genes
17 %
PTEN Sequence Analysis (Prenatal Diagnosis).

By Baylor Miraca Genetics Laboratories (United States).

PTEN
Specificity
100 %
Genes
17 %
Hereditary High Risk Breast Cancer Panel.

By Baylor Miraca Genetics Laboratories (United States).

BRCA1, BRCA2, STK11, TP53, CDH1, PALB2, PTEN
Specificity
15 %
Genes
17 %
Hereditary High Risk Breast Cancer Panel.

By Baylor Miraca Genetics Laboratories (United States).

BRCA1, BRCA2, STK11, TP53, CDH1, PALB2, PTEN
Specificity
15 %
Genes
17 %

We have 558 more panels available in our App

Get the app

Sources and references

You can check the following sources for additional information.

OMIM MESH Rare Disease Symptoms Checker

If you liked this article maybe you will also find interesting the following in-depth articles about other rare diseases, like SPERMATOGENIC FAILURE 10; SPGF10 PARAMYOTONIA CONGENITA OF VON EULENBURG

Need help with a diagnosis?

Learn more about how to achieve it with Mendelian


Learn more